Piper Sandler analyst Joseph Catanzaro downgrades $ESSA Pharma (EPIX.US)$ to a hold rating, and adjusts the target price from $15 to $2.
According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 10.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $ESSA Pharma (EPIX.US)$'s main analysts recently are as follows:
Following a prespecified futility analysis, it was revealed that Essa Pharma's masofaniten failed to achieve the desired efficacy profile in the Phase 2 enzalutamide combination study. The company will cease all development of this candidate. Further details are anticipated as the company embarks on a strategic review to explore alternatives that could enhance shareholder value.
The company has ceased all masofaniten programs following an interim analysis from its Phase 2 trial, which did not demonstrate any advantage of the combination therapy over the monotherapy in metastatic castration-resistant prostate cancer. The quick decision to halt these programs and concentrate on strategic alternatives is deemed judicious, despite the negative outcome. The lack of clarity regarding future direction and the absence of additional assets in various stages of development are contributing factors to the change in outlook.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派傑投資分析師Joseph Catanzaro下調$ESSA Pharma (EPIX.US)$至持有評級，並將目標價從15美元下調至2美元。
根據TipRanks數據顯示，該分析師近一年總勝率為44.8%，總平均回報率為10.3%。
此外，綜合報道，$ESSA Pharma (EPIX.US)$近期主要分析師觀點如下：
經過預先規定的徒勞分析，發現Essa Pharma的masofaniten在2期恩雜魯胺聯合研究中未能達到預期的療效。該公司將停止對該候選人的所有開發。隨着公司開始進行戰略審查，以探索可以提高股東價值的替代方案，預計會有更多細節。
在對其2期試驗進行中期分析後，該公司已停止所有masofaniten項目，該試驗沒有顯示聯合療法在轉移性去勢抵抗性前列腺癌中與單一療法相比有任何優勢。儘管結果不利，但迅速決定停止這些計劃並專注於戰略選擇被認爲是明智的。未來方向不明確，各個發展階段缺乏額外資產，是前景變化的促成因素。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
